Announcements Trials
Browse Landscape

Phase

Phase 2 34Phase 1/2 10Phase NA 4Phase 1 2Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, T-Cell 2Myelodysplastic Syndromes 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Myeloid, Acute 1Leukemia 1Immunoblastic Lymphadenopathy 1

Interventions

Cytarabine 68Cyclophosphamide 44Methotrexate 41Daunorubicin 38Etoposide 34Vincristine 30Mercaptopurine 28Dexamethasone 24Radiotherapy 22Idarubicin 22Asparaginase 21Thioguanine 20Doxorubicin 19Prednisone 17Peripheral Blood Stem Cell Transplantation 17Imatinib Mesylate 16Busulfan 16pegaspargase 15Mitoxantrone 15Filgrastim 13Leucovorin 11fludarabine phosphate 10Hydrocortisone 10nilotinib 9Tretinoin 8Prednisolone 8Cyclosporine 8Hydroxyurea 7Epoetin Alfa 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia × Alemtuzumab × Clear all
NCT00564512 2013-07-25

Fludarabine, Cyclophosphamide, and Rituximab or Alemtuzumab in Treating CLL2007 CLL 2007 FMP

French Innovative Leukemia Organisation

Phase 3 Completed
178 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡